Zoetis Inc. (NYSE:ZTS) Shares Sold by Mackenzie Financial Corp

Mackenzie Financial Corp decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 6.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 153,245 shares of the company’s stock after selling 10,575 shares during the quarter. Mackenzie Financial Corp’s holdings in Zoetis were worth $30,246,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Blue Bell Private Wealth Management LLC raised its stake in Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after acquiring an additional 89 shares during the period. Evermay Wealth Management LLC raised its stake in Zoetis by 439.3% during the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after acquiring an additional 123 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in Zoetis by 430.8% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after acquiring an additional 112 shares during the period. Worth Asset Management LLC acquired a new stake in shares of Zoetis in the first quarter valued at approximately $26,000. Finally, Moisand Fitzgerald Tamayo LLC increased its stake in shares of Zoetis by 105.5% in the third quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock valued at $33,000 after purchasing an additional 96 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 363 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the sale, the executive vice president now directly owns 20,417 shares in the company, valued at $4,037,257.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.12% of the stock is currently owned by insiders.

Zoetis Price Performance

NYSE ZTS opened at $151.94 on Thursday. Zoetis Inc. has a 12 month low of $148.48 and a 12 month high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The firm has a market capitalization of $69.49 billion, a PE ratio of 29.97, a P/E/G ratio of 2.34 and a beta of 0.85. The company’s 50 day simple moving average is $177.35 and its 200 day simple moving average is $180.39.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. Zoetis’s revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.15 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.14%. The ex-dividend date is Thursday, April 18th. Zoetis’s payout ratio is 34.12%.

Analyst Ratings Changes

Several equities research analysts have commented on ZTS shares. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Stifel Nicolaus dropped their price target on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd. Piper Sandler restated an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday. Barclays raised their price target on shares of Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a research note on Wednesday, February 14th. Finally, The Goldman Sachs Group raised their price target on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $221.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.